Professor Nicholas Turner, from the Institute of Cancer Research, tells Sky News that capivasertib is a "great success story ...

"People with advanced breast cancer would value treatments like capivasertib that can be given when limited options exist and ...

A "huge breakthrough" in breast cancer treatment has arrived with the NHS approval of a twice-daily pill for the most common ...

The National Institute for Health and Care Excellence has now approved capivasertib for use on the NHS - we look at who could ...

The UK National Institute for Health and Care Excellence has recommended a targeted twice daily drug treatment that could help around 3000 women a year with advanced breast cancer in England and Wales ...

Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in ...

A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

"People with advanced breast cancer would value treatments like capivasertib that can be given when limited options exist and because it may delay the need for chemotherapy and its associated side ...

The study showed that capivasertib plus fulvestrant extended progression-free survival to 7.3 months, compared with 3.1 months for patients on placebo plus fulvestrant. The drug was approved by ...

A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run ...